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Abstract 
The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish 
Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected and 28.2% 
cirrhotic). Of these, 72.9% of patients that were recognized as priority for HCV treatment according to the Spanish 
Strategic Plan (≥F2, transplant or extrahepatic manifestations), initiated treatment during 2015. Globally, SVR12 was 
achieved in 96.5% of patients. The implementation of the Spanish Strategic Plan has been critical to advance in HCV 
cure, but 27.1% of priority patients still remain awaiting HCV treatment initiation. 
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1. BACKGROUND 
HCV infection is an important health problem affecting more than 150 million people worldwide and 
about 475 000 people in Spain,[1][2] and can lead to significant morbidity and mortality.[3] The 
introduction of high-effective and well tolerated direct-acting antivirals (DAA) has allowed for shorter 
treatment regimens and offered new opportunities for previously excluded groups. Additionally, these 
newer regimens have shown to be cost-effective across all fibrosis stages.[4, 5] However, their current 
high cost only allows a restricted number of patients to access treatment. In May 2015, the Spanish 
National Health Service published a Strategic Plan to face HCV infection. The objective of this Plan was 
to effectively address the prevention, diagnosis, treatment, and monitoring of HCV-infected patients.[2] 
 
The aim of the study was to characterize HCV infection in Northwest Spain and evaluate the impact 
of the Spanish Strategic Plan in this population. 
2. MATERIALS AND METHODS 
This is a transversal observational study. Patients with chronic HCV infection in two hospitals of 
Northwest Spain were included in the period June 2014 to December 2015 (n = 387). This sample size 
allows to estimate parameters of interest with a confidence interval of 95% (α = 0.05) and a precision 
±5%. 
 
The research protocol was approved by the regional ethics committee (“Comité Ético de Investigación 
Clínica de Galicia,” register code 2013/249). All patients participating in the study signed the informed 
consent. 
 
Epidemiological, clinical, and virological characteristics were recorded. Liver fibrosis was measured 
by transient elastography. Regimen and duration of treatment were recorded in those patients who 
initiated HCV treatment during 2015. Treatment efficacy was measured as sustained virological response 
(SVR12) defined as HCV-RNA below the level of detection recorded 12 weeks after treatment 
discontinuation. 
 
The statistical analysis was performed using the Statistical Package for the Social Sciences software 
(SPSS 19.0, Chicago, IL). Categorical variables were presented as number of cases or percentage and 
compared by X
2
 test or Fisheŕs exact test, when appropriate. Continuous variables were expressed as 
median (interquartile range) and compared by non-parametric Mann-Whitney and Kruskal-Wallis test, 
when appropriate. A P-value <0.05 was considered statistically significant. 
3. RESULTS 
A total of 387 patients were included. Of these, 72.6% were men; 60.9% (n = 223) HIV/HCV 
coinfected patients and 28.2% (n = 100) cirrhotic. Epidemiological, clinical, laboratory parameters, and 
virological characteristics previous to HCV-treatment initiation are shown in Table 1. Genotype 1 was the 
most common one (66.2%) followed by genotype 3 (16.8%). Overall, 4.4% of patients had previous 
hepatic decompensation: hydropic decompensation (3.9%), encephalopathy (1.3%), and/or 
gastrointestinal bleeding (0.8%). In addition, 1% of patients had hepatocellular carcinoma and 3.9% 
extrahepatic manifestations of HCV infection. Among treatment-experienced (34.4%) patients, 81.8% 
had received pegylated-interferon (Peg-IFN) and ribavirin (RBV) regimen, and 15.2% Peg-
IFN + RBV + boceprevir/telaprevir. Response to previous HCV treatment was: 31.8% null response, 
25.8% relapse, 21.2% intolerance to Peg-IFN + RBV, 10.6% partial response, and 10.6% unknown 
response. 
Table 1. Epidemiological, clinical, and virological characteristics of HCV infection and DAA-regimens used to treat HCV infection 
during 2015 
Characteristics HCVmono (n = 143) HIV/HCV (n = 223) P Total (n = 387) 
Median time with HCV infection (IQR), years 15 (8-19) 18 (13-23)  < 0.001 17 (11-21) 
Median age (IQR), years 50 (43-55) 49 (44-53) 0.163 49 (45-54) 
Male sex (%) 75.5 74 0.742 72.6 
Route of transmission (%)  < 0.001   
IDU 44.8 85.7   69.7 
Not known 47.6 7.6   23.2 
Other 7.7 6.7   7.1 
Median AST (IQR), mg/dL 37 (26-59) 42 (30-65) 0.051 39 (28-61) 
Median ALT (IQR), mg/dL 47 (25-88) 46 (32-78) 0.595 45 (29-78) 
HBsAg (%) 0 0.5 0.999 0.3 
Prior HCV treatment (%) 0.901   
Naive 65.7 66.4   65.6 
Treatment-experienced 34.3 33.6   34.4 
Median HCV-RNA (IQR), log10 UI/mL 6.01 (5.03-6.48) 6.21 (5.59-6.65) 0.007 6.13 (5.24-6.58) 
IL-28B polymorphism (%) 0.019   
CC 24.3 41.5   36.3 
CT 61.4 42.1   47.9 
TT 14.3 16.5   15.8 
HCV genotype (%) 0.001*   
1a 43 41.7   41.5 
1b 30.3 16.1   23.1 
1 no subtype 0.7 1.3   1.6 
2 3.5 0.4   1.8 
3 13.4 20.6   16.8 
4 9.2 19.7   15.3 
Liver fibrosis (%)   0.364   
F0-F1 29.2 38.5   34.4 
F2 24.6 20   22 
F3 16.9 14.6   15.5 
F4 29.2 26.8   28.2 
Median liver fibrosis (IQR), KPa 8.8 (6.9-14.5) 8.5 (6.1-13.4) 0.299 8.7 (6.3-14.3) 
HCV treatment during 2015 (%) 64.3 42.4  < 0.001 52.7 
Regimen of treatment (%) 
DAA (SOF or SMV) + Peg-IFN + RBV 6.5 0   2.9 
SOF + DAC ± RBV 14.1 25.5   18.6 
SOF + LDV ± RBV 43.5 59.6   51 
SOF + SMV ± RBV 9.8 8.5   10.3 
SOF + RBV 6.5 0   3.4 
3D 15.2 2.1   10.3 
2D 4.3 1.1   3.4 
Duration of treatment (%) 0.103**   
8 weeks 1.1 0   0.5 
12 weeks 74.4 64.5   70.6 
24 weeks 24.4 35.5   28.9 
     
 
HCVmono, hepatitis C monoinfection; IQR, interquartile range; IDU, intravenous drug users; AST, aspartate aminotransferase; mg, 
miligrams; dL, decilitre; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HCV-RNA, plasmatic viremia of 
HCV; F0-F4, grade of liver fibrosis measured by transient elastography; KPa, kilopascals; DAA, direct-acting antivirals; SOF, 
sofosbuvir; SMV, simeprevir; Peg-IFN, pegylated interferon; RBV, ribavirin; DAC, daclatasvir; LDV, ledipasvir; 3D, 
ombitasvir + paritaprevir/ritonavir + dasabuvir; 2D, ombitasvir + paritaprevir/ritonavir. 
*Comparing genotypes 1a, 1b, 3, and 4. 
**Comparing 8-12 versus 24 weeks.
Regarding HIV/HCV patients, 95.9% received antiretroviral treatment (ART) with a combination of 
two nucleoside reverse transcriptase inhibitors and a protease inhibitor (43.8%), a non-nucleoside reverse 
transcriptase inhibitor (28.8%) or an integrase inhibitor (13.5%) while 13.5% received other regimens. 
Median CD4 count at the moment of the study was 566 (312-750) cells/mm
3
 and 86.7% of patients under 
ART had suppressed viremia. 
 
During 2015, 52.7% of HCV-infected patients initiated treatment. According to the Spanish Strategic 
Plan for HCV infection, 66.5% of all patients should be prioritized for HCV treatment (liver fibrosis ≥F2, 
transplant or extrahepatic manifestations). Of these, 72.9% initiated HCV treatment during 2015. 
Combinations of DAA and duration of HCV treatment are shown in Table 1. 
 
Overall, 96.5% of HCV patients achieved SVR12. SVR12 rates in different subgroups are shown in 
Figure 1. No differences were observed according to previous HCV treatment (P = 0.086), HIV/HCV 
coinfection (P = 0.395), HCV genotype (1 vs. non-1 genotype, P = 0.999; and 3 vs. non-3, P = 0.181) or 
liver fibrosis (F2-F3 vs. F4, P = 0.408). 
 
 
 
Figure 1. Sustained virological response at 12 weeks (SVR12) after finishing HCV 
treatment. A: Global SVR12 and SVR12 according to genotype, liver fibrosis and 
HIV/HCV coinfection. B: SVR12 according to DAA-based regimen, duration of HCV 
treatment and previous exposure to HCV treatment. G1a, genotype 1a; G1b, genotype 
1b; G2, genotype 2; G3, genotype 3; G4, genotype 4; F0-F1, liver fibrosis measured by 
transient elastography <7.5 KPa; F2, liver fibrosis measured by transient elastography 
7.5-9.4 KPa; F3, liver fibrosis measured by transient elastography 9.5-12.5 KPa; F4, 
liver fibrosis measured by transient elastography >12.5 KPa; HCV-mono, HCV mono-
infected patients; HIV/HCV, HIV and HCV coinfected patients; DAA, direct-acting 
antivirals (includes SOF or SMV); PegIFN, pegylated interferon; RBV, ribavirin; SOF, 
sofosbuvir; DAC, daclatasvir; LDV, ledipasvir; SMV, simeprevir; 3D, 
ombitasvir + paritapevir/ritonavir + dasabuvir; 2D, ombistasvir + paritaprevir/ritonavir; 
8 w, 8 weeks of HCV treatment; 12 w, 12 weeks of HCV treatment; 24 w, 24 weeks of 
HCV treatment; TE, previous treatment-experienced HCV patients 
  
Among failures (n = 6), five were treatment-experienced (Peg-IFN-based regimens), four cirrhotic, 
and one was HIV/HCV coinfected. Regarding HCV genotypes, there were four patients with genotype 1 
(only one with genotype 1a although subtype was not determined in one patient) and two with genotype 
3. All failures but two (intolerance to Peg-IFN-based regimen and hepatic decompensation with death) 
were relapses. Of these, three patients were re-treated (Peg-IFN + RBV + sofosbuvir (SOF) and 
SOF + ledipasvir + RBV, and both achieved SVR12 while another is on-treatment with 
SOF + daclatasvir + RBV) and one patient died before re-treatment due to hepatocellular cancer. 
Resistance test was performed in only one patient and no resistance mutations were found. 
4. DISCUSSION 
This study characterizes chronic HCV infection in 387 patients in Northwest Spain and the impact of 
the Spanish Strategic Plan on HCV cure last year. This cohort had 28.2% of patients with cirrhosis and a 
high prevalence of HIV/HCV patients (60.9%). The introduction of the Spanish Strategic Plan in 2015 
has allowed to treat half (52.7%) of all HCV patients with different DAA-combinations and SVR12 rates 
over 96%. 
 
The distribution of HCV genotypes is similar throughout Western Europe with some local 
differences.[1, 6-8] The prevalence of HCV infection in Spain is among the highest in Europe and several 
studies reported genotype 1 as the most common one, similarly to our cohort (66.2%).[9-11] In addition, 
HCV genotypes are usually associated to different routes of transmission. In fact, genotypes 1a, 3, and 4 
are more common among intravenous drug users[1, 6-8, 10, 12] and represent 82% of HIV/HCV patients 
in our cohort. 
 
Cirrhosis had similar prevalence in both HCV-monoinfected and HIV/HCV patients (29.2% vs. 
26.8%, respectively). Since the widespread introduction of ART regimens, data on the effect of HIV 
coinfection on liver fibrosis progression and its complications have been controversial.[13-16] An 
improved control of HIV infection with earlier initiation of a less hepatotoxic ART and higher CD4 
counts could explain similar rates of cirrhosis in both HCV-monoinfected and HIV/HCV patients 
observed in our cohort. 
 
The development of DAA has allowed a significant improvement in rates of SVR12. However, those 
patients involved in clinical trials tend to have more favorable outcomes than patients in the real-world 
mainly due to strict patient selection. In our cohort, rates of SVR12 were consistently high across all 
subgroups evaluated, ranging from 83.3% to 100%. Cirrhosis and HIV/HCV coinfection had been 
previously identified as independent predictors of virological failure.[17] However, we found no 
significant differences in SVR12 based on HIV/HCV coinfection or liver fibrosis. Despite the high rate 
(98.5%) of SVR12 observed in our cohort of HIV/HCV patients, it is noteworthy that less patients have 
initiated treatment compared with HCV-monoinfected (42.4% and 64.3%, respectively). Effectiveness in 
HIV/HCV patients was similar to HCV-monoinfected and concordant with clinical trials and real-world 
published data.[5, 18] Therefore, HIV/HCV population appear to be no longer a hard-to-treat population 
and should be treated as HCV-monoinfected patients.[19] 
 
In this scenario, the eradication of HCV infection is a desirable and achievable goal for the next years. 
A successful treatment results in curing HCV infection and decreasing the risk of HCV-related 
complications.[20] However, enthusiasm for efficacy and safety of DAA has been dampened by their 
high price and some countries have restricted these therapies to advanced-stage patients. This is the case 
of Spain, where the implementation of the Strategic Plan to face HCV infection recommends the priority 
of HCV treatment for those patients with liver fibrosis ≥F2, transplant or extrahepatic manifestations. 
According to this, 66.5% of our cohort should be prioritized and 72.9% of these patients initiated HCV 
treatment during 2015. 
 
This study has some limitations. The high prevalence of HIV/HCV coinfected patients could represent 
a selection bias and safety of HCV treatment was not evaluated. 
  
In summary, the Spanish Strategic Plan has had a great impact on our medical area because it has 
allowed to treat half of all HCV-infected patients and almost 75% of patients who were candidates to 
prioritize HCV treatment. Effectiveness was very high and similar to that observed in the context of 
clinical trials, including cirrhotic and HIV/HCV coinfected patients. Therefore, access to DAA will 
probably allow to avoid HCV-related morbidity and costs of HCV complications. 
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